GlassScriptPhysician profile
James M Miller
NPI 1477635613
$1,752.35
in general payments reported to CMS, 2019-2025
9 companies · $609 in 2025
The $609 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.97 · 2022: $320 · 2023: $111 · 2024: $613 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $620.00 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $239.98 | 2024-2025 | Precision7, Precision 1, Total30 |
| Abbvie INC. | $213.80 | 2022-2023 | |
| Eyevance Pharmaceuticals LLC | $161.34 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $145.18 | 2024 | Xdemvy |
| Astellas Pharma US INC | $125.40 | 2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.97 | 2019 | |
| Sun Pharmaceutical Industries INC. | $91.00 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $55.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.